Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02381522 · ClinicalTrials.gov registry record · NA
Remote Ischemic Pre-conditioning in Subarachnoid Hemorrhage
A NA study, sponsored by Loma Linda University.
- Completed
- Registry status
- NA
- Development phase
- 26
- Enrollment target
NCT02381522: Completed NA study, sponsored by Loma Linda University.
NCT02381522 is a NA study that has completed, run by Loma Linda University. The registered enrollment target is 26 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02381522, a NA study, has completed, sponsored by Loma Linda University.
- COMPLETED
- Registry status
- NA
- Development phase
- 26 participants
- Enrollment target
Study Summary
The purpose of the study is to investigate if briefly stopping blood flow to the patient's leg will lead to the patient's body being better able to tolerate possible decreased blood flow to regions of the brain which otherwise frequently happens after subarachnoid hemorrhage. Previous studies show that various organs such as the heart, brain or kidney can tolerate longer periods of decreased blood flow if prior to that insult shorter periods of decreased blood flow were experienced.
Primary Outcome
RIPC or Sham RIPC will be done for two weeks or duration of patients hospital stay if shorter than 2 weeks. TCD measurements will be done during that time.
Interventions
- OTHER Remote Ischemic Pre-conditioning
- OTHER Sham RIPC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2015-03-01 |
| Est. Completion | 2017-12-20 |
| Phase | NA |
What the finished NCT02381522 record still lists
NCT02381522 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 26 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 2 interventions - of which Remote Ischemic Pre-conditioning is the first listed.
NCT02381522 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02381522 about?
NCT02381522 is a clinical study titled "Remote Ischemic Pre-conditioning in Subarachnoid Hemorrhage". The purpose of the study is to investigate if briefly stopping blood flow to the patient's leg will lead to the patient's body being better able to tolerate possible decreased blood flow to regions of the brain which otherwise frequently happens after subarachnoid hemorrhage. Previous studies show ...
What is the current status of trial NCT02381522?
This trial is currently completed. It is a NA study. The enrollment target is 26 participants. The study started on 2015-03-01. Estimated completion is 2017-12-20.
What interventions are being tested in trial NCT02381522?
The interventions under investigation include: Remote Ischemic Pre-conditioning (OTHER), Sham RIPC (OTHER).
Who is sponsoring clinical trial NCT02381522?
This trial is sponsored by Loma Linda University, which has 237 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02381522's enrollment target sits among peer trials
26 1710th of 2000 higher than 289 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02646475 · 26 participants · Phase 1
Metabolic Effects of Angiotensin-(1-7)
- NCT03603223 · 26 participants · Phase 2
Pembrolizumab in Treating Participants With Leukoplakia
- NCT04063592 · 26 participants · NA
AMI Construction in Lower Extremity Residual Limbs
- NCT04906460 · 26 participants · Phase 1
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI